In patients with severe medically refractory gastroparesis (such as those requiring nutritional support), how effective and cost effective is gastric electrical stimulation (EnterraTM device) in reducing symptoms, reducing requirement for nutritional support or hospitalisation and improving quality of life, when compared with medical or alternative surgical management?
McIntosh H
Record ID 32013000477
English
Authors' recommendations:
Summary
The evidence base for GES consists mainly of uncontrolled observational studies. GES is associated with statistically significant reductions in symptom frequency and severity, reduced need for hospital
admissions and improved quality of life for patients with severe medically refractory gastroparesis.
Around 10% of patients require device removal.
While there is evidence of symptom reduction with gastric electrical stimulation, there is a lack of cost
effectiveness evidence.
An ongoing double blind randomised controlled trial (Medico-economic Evaluation of EnterraTM therapy) aims to recruit 220 patients and examine both the clinical effectiveness and healthcare
utilisation associated with GES in patients with severe refractory symptoms over a 28 month study
period. The results which are due in 2013 are likely to be influential.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/earlier_scoping_reports/technologies_scoping_report_5.aspx
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland, United Kingdom
MeSH Terms
- Gastroparesis
Contact
Organisation Name:
Scottish Health Technologies Group
Contact Address:
Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name:
his.shtg@nhs.scot
Contact Email:
his.shtg@nhs.scot
Copyright:
Healthcare Improvement Scotland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.